An experimental gene therapy offers hope for rapid improvement in the night vision of adults who have a congenital form of childhood-onset blindness, researchers report.
In this ongoing clinical trial at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania, in Philadelphia, researchers delivered AAV gene therapy (when an adenovirus is used to ferry genetic material to targeted cells) into the retina of one eye for each of the study patients.
